Paméla Lavoie

792 total citations
31 papers, 661 citations indexed

About

Paméla Lavoie is a scholar working on Physiology, Cell Biology and Organic Chemistry. According to data from OpenAlex, Paméla Lavoie has authored 31 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Physiology, 11 papers in Cell Biology and 10 papers in Organic Chemistry. Recurrent topics in Paméla Lavoie's work include Lysosomal Storage Disorders Research (28 papers), Cellular transport and secretion (10 papers) and Trypanosoma species research and implications (10 papers). Paméla Lavoie is often cited by papers focused on Lysosomal Storage Disorders Research (28 papers), Cellular transport and secretion (10 papers) and Trypanosoma species research and implications (10 papers). Paméla Lavoie collaborates with scholars based in Canada, United States and France. Paméla Lavoie's co-authors include Christiane Auray‐Blais, Michel Boutin, René Gagnon, Joe T.R. Clarke, Bruno Maranda, Yan An, Haoyue Zhang, David S. Millington, Sarah P. Young and Daniel G. Bichet and has published in prestigious journals such as Analytical Chemistry, International Journal of Molecular Sciences and Analytica Chimica Acta.

In The Last Decade

Paméla Lavoie

30 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paméla Lavoie Canada 14 568 241 211 204 176 31 661
Nobuyuki Ishige Japan 8 259 0.5× 149 0.6× 74 0.4× 83 0.4× 54 0.3× 12 302
H.A. Wisselaar Netherlands 9 258 0.5× 48 0.2× 56 0.3× 154 0.8× 139 0.8× 11 426
Karen Ghauharali Netherlands 6 360 0.6× 119 0.5× 177 0.8× 180 0.9× 264 1.5× 8 488
Paolo Durand Italy 6 229 0.4× 46 0.2× 49 0.2× 114 0.6× 193 1.1× 7 370
Xia Zhan China 13 127 0.2× 38 0.2× 62 0.3× 29 0.1× 181 1.0× 39 376
Rebecca Mardach United States 11 100 0.2× 31 0.1× 82 0.4× 57 0.3× 193 1.1× 17 351
T. Tokoro Japan 8 242 0.4× 30 0.1× 85 0.4× 89 0.4× 170 1.0× 21 349
Hans‐Joachim Kytzia Germany 8 311 0.5× 100 0.4× 96 0.5× 97 0.5× 236 1.3× 10 408
Irene Mavridou Greece 11 160 0.3× 33 0.1× 70 0.3× 79 0.4× 113 0.6× 20 280
Sun Hee Heo South Korea 10 124 0.2× 54 0.2× 55 0.3× 41 0.2× 138 0.8× 24 311

Countries citing papers authored by Paméla Lavoie

Since Specialization
Citations

This map shows the geographic impact of Paméla Lavoie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paméla Lavoie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paméla Lavoie more than expected).

Fields of papers citing papers by Paméla Lavoie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paméla Lavoie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paméla Lavoie. The network helps show where Paméla Lavoie may publish in the future.

Co-authorship network of co-authors of Paméla Lavoie

This figure shows the co-authorship network connecting the top 25 collaborators of Paméla Lavoie. A scholar is included among the top collaborators of Paméla Lavoie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paméla Lavoie. Paméla Lavoie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Auray‐Blais, Christiane, Paméla Lavoie, Aneal Khan, et al.. (2023). Fabry Disease Biomarkers in Patients Switched From Enzyme-Replacement Therapy to Migalastat Oral Chaperone Therapy. Bioanalysis. 15(23). 1421–1437. 1 indexed citations
2.
Mérindol, Natacha, et al.. (2023). Successful reversal of transgene silencing in Chlamydomonas reinhardtii. Biotechnology Journal. 19(1). e2300232–e2300232. 6 indexed citations
3.
Boutin, Michel, et al.. (2023). Multiplex Quantification of Plasma Biomarkers for Patients with Gaucher Disease Type 1. Current Protocols. 3(2). e696–e696.
4.
Boutin, Michel, et al.. (2023). Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots. International Journal of Molecular Sciences. 24(4). 3223–3223. 7 indexed citations
5.
Auray‐Blais, Christiane, Michel Boutin, Paméla Lavoie, & Bruno Maranda. (2021). Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry. International Journal of Neonatal Screening. 7(1). 18–18. 7 indexed citations
6.
Boutin, Michel, Paméla Lavoie, Marie‐Françoise Arthus, et al.. (2020). Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles. International Journal of Molecular Sciences. 21(17). 6114–6114. 4 indexed citations
7.
8.
Auray‐Blais, Christiane, Paméla Lavoie, Anne‐Marie Côté, et al.. (2019). High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. Clinica Chimica Acta. 501. 234–240. 16 indexed citations
9.
10.
Auray‐Blais, Christiane, Paméla Lavoie, Michel Boutin, et al.. (2017). Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clinica Chimica Acta. 466. 185–193. 45 indexed citations
11.
Auray‐Blais, Christiane, Paméla Lavoie, Shunji Tomatsu, et al.. (2016). UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. Analytica Chimica Acta. 936. 139–148. 51 indexed citations
12.
Ferreira, Susana, Christiane Auray‐Blais, Michel Boutin, et al.. (2015). Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clinica Chimica Acta. 447. 96–104. 23 indexed citations
13.
Auray‐Blais, Christiane, David S. Millington, Frits A. Wijburg, et al.. (2015). Urine keratan sulfate (uKS) elevation in lysosomal disorders (LSD): Comparison of uKS levels in Morquio/MPS IV versus non-Morquio LSD. Molecular Genetics and Metabolism. 114(2). S16–S16. 1 indexed citations
14.
Boutin, Michel, et al.. (2015). Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. Clinica Chimica Acta. 452. 191–198. 27 indexed citations
15.
Auray‐Blais, Christiane, Uma Ramaswami, Michel Boutin, et al.. (2014). Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clinica Chimica Acta. 438. 195–204. 59 indexed citations
16.
Auray‐Blais, Christiane, Bruno Maranda, & Paméla Lavoie. (2014). High-throughput tandem mass spectrometry multiplex analysis for newborn urinary screening of creatine synthesis and transport disorders, Triple H syndrome and OTC deficiency. Clinica Chimica Acta. 436. 249–255. 13 indexed citations
17.
Auray‐Blais, Christiane, Michel Boutin, Paméla Lavoie, et al.. (2013). Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring. Molecular Genetics and Metabolism. 108(2). S21–S21. 1 indexed citations
18.
Boutin, Michel, René Gagnon, Paméla Lavoie, & Christiane Auray‐Blais. (2012). LC–MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Clinica Chimica Acta. 414. 273–280. 55 indexed citations
19.
Auray‐Blais, Christiane, et al.. (2012). Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics. Analytical Chemistry. 84(6). 2745–2753. 87 indexed citations
20.
Auray‐Blais, Christiane, Paméla Lavoie, Haoyue Zhang, et al.. (2012). An improved method for glycosaminoglycan analysis by LC–MS/MS of urine samples collected on filter paper. Clinica Chimica Acta. 413(7-8). 771–778. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuyuki Ishige Breakdown of academic impact, for papers by H.A. Wisselaar Breakdown of academic impact, for papers by Karen Ghauharali Breakdown of academic impact, for papers by Paolo Durand Breakdown of academic impact, for papers by Xia Zhan Breakdown of academic impact, for papers by Rebecca Mardach Breakdown of academic impact, for papers by T. Tokoro Breakdown of academic impact, for papers by Hans‐Joachim Kytzia Breakdown of academic impact, for papers by Irene Mavridou Breakdown of academic impact, for papers by Sun Hee Heo
Rankless by CCL
2026